LAMICTAL XR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LAMICTAL XR (LAMICTAL XR).
Lamotrigine inhibits voltage-sensitive sodium channels, stabilizing neuronal membranes and inhibiting the release of excitatory neurotransmitters such as glutamate and aspartate.
| Metabolism | Lamotrigine is primarily metabolized by hepatic glucuronidation via UDP-glucuronosyltransferases (UGT1A4, UGT2B7). It is not significantly metabolized by cytochrome P450 enzymes. |
| Excretion | Primarily renal; ~70% of lamotrigine is excreted in urine as glucuronide conjugates, 10% as parent drug, and 20% via feces. |
| Half-life | Terminal elimination half-life is approximately 25-33 hours in healthy adults, increasing to 50-60 hours in patients taking valproate, and decreasing to 15-27 hours in patients taking enzyme-inducing drugs like carbamazepine, phenytoin, or phenobarbital. |
| Protein binding | Approximately 55% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Approximately 1.0-1.2 L/kg, indicating distribution into total body water and tissues. |
| Bioavailability | Oral bioavailability is approximately 98% for LAMICTAL XR extended-release tablets, with no significant food effect. |
| Onset of Action | Not applicable; lamotrigine is administered orally and requires gradual dose titration to achieve therapeutic levels; clinical effect is typically seen within 1-2 weeks after reaching maintenance dose. |
| Duration of Action | Due to long half-life, once-daily dosing provides steady-state concentrations; duration of action is continuous over the dosing interval, with no acute offset. |
Lamotrigine extended-release tablets: Initial 25 mg orally once daily for 2 weeks, then 50 mg once daily for 2 weeks, then 100 mg once daily for 1 week, then 200 mg once daily; maintenance 200–400 mg once daily as adjunctive therapy for epilepsy. For bipolar disorder, dose titration as per prescribing information; typical maintenance 200 mg once daily.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | For patients with significant renal impairment (CrCl <30 mL/min): reduce maintenance dose by approximately 50%; administer with caution due to reduced clearance and potential accumulation of glucuronide metabolites. |
| Liver impairment | Child-Pugh Class A: reduce initial, escalation, and maintenance doses by approximately 25%; Child-Pugh Class B: reduce by 50%; Child-Pugh Class C: reduce by 75% (or avoid). Slower dose titration recommended. |
| Pediatric use | For children ≥2 years with epilepsy: weight-based dosing per Lamictal XR prescribing information; typical initial 0.3 mg/kg/day (divided once daily for XR) for first 2 weeks depending on concomitant medications; slow titration to maintenance doses approximately 4.5–11.5 mg/kg/day (max 400 mg/day) based on co-therapy (enzyme-inducing AEDs or valproate). Specific regimens require individual calculation. |
| Geriatric use |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LAMICTAL XR (LAMICTAL XR).
| Breastfeeding | Lamotrigine is excreted into breast milk with a milk-to-plasma ratio (M/P) of approximately 0.4-0.6 (range 0.2-1.0). Infant serum levels can reach 25-50% of maternal serum levels. Breastfeeding is generally considered compatible but requires monitoring for infant adverse effects such as rash, drowsiness, poor sucking, and apnea. The benefits of breastfeeding may outweigh risks if maternal treatment is necessary. |
| Teratogenic Risk | Lamotrigine (LAMICTAL XR) is associated with a dose-dependent increased risk of major congenital malformations, particularly oral clefts (cleft lip/palate), in first trimester exposure. The absolute risk for any major malformation is approximately 2-4% at doses ≤200 mg/day, increasing to 4.5-9% at higher doses. Risk is lower than with valproate but higher than unexposed population. Third trimester exposure may increase risk of neonatal withdrawal or serotonin syndrome-like symptoms. Preterm birth and low birth weight have been reported. |
■ FDA Black Box Warning
LAMICTAL XR is associated with a risk of life-threatening serious rashes including Stevens-Johnson syndrome, toxic epidermal necrolysis, and/or rash-related death. The risk is increased in pediatric patients, with high starting doses, exceeding recommended dose escalation, and concomitant use of valproate.
| Common Effects | Skin rash Headache Nausea Vomiting Dryness in mouth Insomnia difficulty in sleeping Sleepiness Dizziness Back pain Abdominal pain Blurred vision Double vision Impaired coordination Nasal congestion stuffy nose Infection |
| Serious Effects |
["History of hypersensitivity to lamotrigine or any component of the formulation","Use in patients with severe rash or hypersensitivity reactions to other antiepileptic drugs (cross-sensitivity)"]
| Precautions | ["Life-threatening serious rashes (Stevens-Johnson syndrome, toxic epidermal necrolysis); discontinue at first sign of rash unless clearly not drug-related","Hemophagocytic lymphohistiocytosis (HLH); discontinue if HLH is suspected","Suicidal thoughts and behavior; monitor for worsening depression or suicidality","Aseptic meningitis; discontinue if symptoms suggest meningitis","Blood dyscrasias; monitor for signs of infection, bruising, or bleeding","Withdrawal seizures; taper dose gradually over at least 2 weeks","Status epilepticus; increased risk in patients with seizure disorders","Risk of rash in pediatric patients; stricter dosing guidelines","Interaction with oral contraceptives; may decrease lamotrigine efficacy","Concomitant use with valproate increases risk of rash; lower starting dose required"] |
Loading safety data…
| No specific dose adjustment solely for age; initiate and titrate cautiously. Monitor renal function and adjust accordingly. Use lowest effective maintenance dose due to potential decreased clearance and increased adverse effects. |
| Fetal Monitoring | Monitor maternal lamotrigine serum concentrations throughout pregnancy, especially before, during, and after delivery; dose adjustments are often required. Perform fetal ultrasound for anatomy screening (including oral cleft assessment) at 18-20 weeks gestation. Assess for neonatal adverse effects post-delivery, including sedation, poor feeding, and withdrawal symptoms. Monitor for maternal rash, signs of Stevens-Johnson syndrome, and liver function tests periodically. |
| Fertility Effects | Lamotrigine does not appear to have significant adverse effects on fertility in animal studies. In humans, no definitive evidence of impaired male or female fertility. However, menstrual irregularities and anovulatory cycles have been reported in some women. Use during pregnancy does not affect future fertility. |
| Food/Dietary | No specific food interactions are reported for lamotrigine. Grapefruit juice does not significantly affect lamotrigine metabolism. However, patients should maintain consistent dietary habits, and avoid rapid dietary changes that could affect GI motility or absorption. Alcohol may increase CNS depression. |
| Clinical Pearls | LAMICTAL XR (lamotrigine extended-release) is indicated for maintenance therapy of bipolar I disorder to delay the time to occurrence of mood episodes. Titrate slowly to minimize risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN); typical starting dose 25-50 mg/day increased by 25-50 mg every 1-2 weeks. If valproate is coadministered, halve the dose and double the titration rate due to inhibition of lamotrigine clearance. Conversely, enzyme-inducing antiepileptics (e.g., phenytoin, carbamazepine, phenobarbital) require doubling of target dose. Monitor for rash, especially in first 2-8 weeks; any sign of rash should prompt immediate discontinuation unless clearly drug-unrelated. LAMICTAL XR has a longer half-life (about 33 hours) and allows once-daily dosing; do not chew or crush tablets. |
| Patient Advice | Swallow tablets whole; do not cut, chew, or crush. · Take exactly as prescribed; do not stop abruptly without medical advice. · Report any skin rash, hives, blisters, or mucosal lesions immediately. · Contact doctor if you experience fever, swollen lymph nodes, or flu-like symptoms. · If you miss a dose, skip it; do not double the next dose. · Use reliable contraception if needed; this drug may reduce effectiveness of hormonal contraceptives. · Avoid driving or hazardous activities until you know how this drug affects you. · Keep a strict schedule; take at the same time each day. |